Legend Biotech Corp ADR (LEGN): Next-Year EPS Estimate 493.73%
As of 2026-11-12, Legend Biotech Corp ADR (LEGN) has a next-year EPS growth estimate of 493.73%. Featured in 3 EPS revision reports, most recently on 2026-04-23.
On 2026-11-12, analyst consensus for LEGN's next-year EPS growth shifted from 591.38% to 493.73% — a negative change of 97.65 percentage points. Current-year growth is projected at 110.14%.
What's Driving This
LEGN has been rising primarily because analysts sharply raised the next-year EPS growth estimate from 1246.72% to 1357.95%, a 111.23 percentage-point upgrade that remains the current estimate. The J&J headline about exiting biotechs while keeping stakes in rumored acquisition targets does not clearly identify a LEGN-specific catalyst such as an earnings beat, contract win, guidance raise, or product launch. No subsequent revision data show the trend continuing beyond the initial upgrade.
Generated 2026-11-09 from news as of 2026-11-09
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 493.73%
- EPS growth this year
- 110.14%
- EPS next quarter (est)
- $0.05
- Last price
- $18.54
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 493.73% | 110.14% | $0.05 | $18.54 |
| 2026-11-11 | 591.38% | 108.60% | $0.05 | $19.54 |
| 2026-11-10 | 18681.79% | 99.65% | $0.03 | $20.41 |
| 2026-11-09 | 1357.95% | 94.69% | $0.00 | $24.29 |
| 2026-11-07 | 1357.95% | 94.69% | $0.00 | $23.40 |
| 2026-11-06 | 1357.95% | 94.69% | $0.00 | $23.40 |
| 2026-11-05 | 1357.95% | 94.69% | $0.00 | $22.54 |
| 2026-11-04 | 1357.95% | 94.69% | $0.00 | $22.77 |
| 2026-11-03 | 1357.95% | 94.69% | $0.00 | $21.48 |
| 2026-11-02 | 1357.95% | 94.69% | $0.00 | $21.10 |
| 2026-10-31 | 1357.95% | 94.69% | $0.00 | $21.63 |
| 2026-10-30 | 1357.95% | 94.69% | $0.00 | $21.63 |
| 2026-10-29 | 1357.95% | 94.69% | $0.00 | $22.30 |
| 2026-10-28 | 1357.95% | 94.69% | $0.00 | $22.53 |
| 2026-10-27 | 1357.95% | 94.69% | $0.00 | $21.56 |
| 2026-10-26 | 1357.95% | 94.69% | $0.00 | $20.39 |
| 2026-10-23 | 1357.95% | 94.69% | $0.00 | $19.27 |
| 2026-10-22 | 1357.95% | 94.69% | $0.00 | $18.90 |
| 2026-10-21 | 1357.95% | 94.69% | $0.00 | $18.63 |
| 2026-10-20 | 1357.95% | 94.69% | $0.00 | $19.01 |
| 2026-10-19 | 1357.95% | 94.69% | $0.00 | $18.65 |
| 2026-10-16 | 1357.95% | 94.69% | $0.00 | $18.48 |
| 2026-10-15 | 1357.95% | 94.69% | $0.00 | $19.80 |
| 2026-10-14 | 1357.95% | 94.69% | $0.00 | $19.04 |
| 2026-10-13 | 1246.72% | 94.19% | $0.00 | $17.88 |
| 2026-10-12 | 1253.81% | 94.19% | $0.00 | $17.80 |
| 2026-10-11 | 1297.01% | 94.23% | $0.00 | $18.62 |
| 2026-10-10 | 1297.01% | 94.23% | $0.00 | $18.62 |
| 2026-10-09 | 1297.01% | 94.23% | $0.00 | $18.62 |
| 2026-10-08 | 1354.51% | 94.29% | $0.00 | $18.71 |
Reports Featuring LEGN
Recent News
- LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI TherapyStocktwits
- Legend Biotech's Big EPS Beat Masks Slowing Carvykti Growth And An Effective Guide-Down For Q4 And 2027Earnings Whispers
- Legend Biotech Reports Third Quarter 2026 Results and Recent HighlightsGlobeNewswire
- Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition TargetsBarrons.com
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Legend Biotech Corp ADR's next-year EPS growth estimate?▾
As of 2026-11-12, Legend Biotech Corp ADR (LEGN) has a next-year EPS growth estimate of 493.73%, based on analyst consensus.
When was the latest EPS estimate revision for LEGN?▾
The most recent revision occurred on 2026-11-12, when analysts adjusted the next-year EPS growth estimate from 591.38% to 493.73%.
What sector and industry does Legend Biotech Corp ADR belong to?▾
Legend Biotech Corp ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. LEGN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Legend Biotech Corp ADR (LEGN) appears here because it was detected by our daily top-EPS-revision-performer screen.